Korro Bio Chief Executive Officer Ram Aiyar, Ph.D., MBA, to Present at Upcoming Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Korro Bio, Inc., a biotechnology company developing single-base RNA editing therapies, today announced that Ram Aiyar, Ph.D., MBA, chief executive officer, will present at the Barclays Global Healthcare Conference and the WuXi Healthcare Forum this month.
Dr. Aiyar will be presenting at the Barclays Global Healthcare Conference on March 9, 2021 at 7:30 a.m. EST.
At the WuXi Healthcare Conference, Dr. Aiyar will participate in a panel on “Engineering the Future of Health” on March 16, 2021 at 11:35 a.m. EST. He will also participate in a CEO roundtable.
About Korro Bio
Korro is leading the next frontier in RNA therapeutics. Its proprietary platform, OPERA (Oligonucleotide Promoted Editing of RNA), harnesses the body’s own RNA editing system to make a precise edit to a single-base. Korro’s therapeutic approach utilizes synthetic oligonucleotides to repair disease-causing mutations at the RNA level. This approach can also be used to create therapeutically beneficial versions of proteins to improve patient outcomes. Korro’s programs target a broad portfolio of innovative RNA editing therapies in the liver, eye and central nervous system. The company was founded in 2018 by Atlas Venture and is funded by Atlas Venture, New Enterprise Associates, Wu Capital, Qiming Venture Partners USA, Surveyor Capital (a Citadel company), Cormorant Asset Management, MP Healthcare Venture Management and Alexandria Venture Investments. For more information, visit korrobio.com.
Ten Bridge Communications
Source: Korro Bio, Inc.